請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79225
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳美環邱舜南 | zh_TW |
dc.contributor.advisor | Mei-Hwan WuShuenn-Nan Chiu | en |
dc.contributor.author | 林杏佳 | zh_TW |
dc.contributor.author | Hsin-Chia Lin | en |
dc.date.accessioned | 2022-11-16T17:02:27Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2022-11-14 | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2002-01-01 | - |
dc.identifier.citation | 1. Wu MH, Chen HC, Lu CW, Wang JK, Huang SC, Huang SK. Prevalence of congenital heart disease at live birth in Taiwan. J Pediatr. May 2010;156(5):782-5. doi:10.1016/j.jpeds.2009.11.062 2. Kim SJ. Heterotaxy syndrome. Korean Circ J. May 2011;41(5):227-32. doi:10.4070/kcj.2011.41.5.227 3. Shao PL, Chen MY, Wu MH, Wang JK, Huang LM, Chiu SN. Nosocomial Severe Bacterial Infection After Cardiac Surgery for Complex Congenital Heart Disease in Heterotaxy Syndrome. Pediatr Infect Dis J. Aug 2020;39(8):e163-e168. doi:10.1097/INF.0000000000002672 4. Wu MH, Wang JK, Chiu SN, et al. Twin atrioventricular nodes, arrhythmias, and survival in pediatric and adult patients with heterotaxy syndrome. Heart Rhythm. Apr 2021;18(4):605-612. doi:10.1016/j.hrthm.2020.12.012 5. McNamara JR, McMahon A, Griffin M. Perioperative Management of the Fontan Patient for Cardiac and Noncardiac Surgery. J Cardiothorac Vasc Anesth. Jan 2022;36(1):275-285. doi:10.1053/j.jvca.2021.04.021 6. Gewillig M. The Fontan circulation. Heart. Jun 2005;91(6):839-46. doi:10.1136/hrt.2004.051789 7. Egbe AC, Reddy YNV, Khan AR, et al. Venous congestion and pulmonary vascular function in Fontan circulation: Implications for prognosis and treatment. Int J Cardiol. Nov 15 2018;271:312-316. doi:10.1016/j.ijcard.2018.05.039 8. Kverneland LS, Kramer P, Ovroutski S. Five decades of the Fontan operation: A systematic review of international reports on outcomes after univentricular palliation. Congenit Heart Dis. Mar 2018;13(2):181-193. doi:10.1111/chd.12570 9. Marathe SP, Cao JY, Celermajer D, et al. Outcomes of the Fontan Operation for Patients With Heterotaxy: A Meta-Analysis of 848 Patients. Ann Thorac Surg. Jul 2020;110(1):307-315. doi:10.1016/j.athoracsur.2019.11.027 10. Marathe SP, Zannino D, Cao JY, et al. Heterotaxy Is Not a Risk Factor for Adverse Long-Term Outcomes After Fontan Completion. Ann Thorac Surg. Aug 2020;110(2):646-653. doi:10.1016/j.athoracsur.2019.11.015 11. Chowdhury UK, Airan B, Kothari SS, et al. Specific issues after extracardiac fontan operation: ventricular function, growth potential, arrhythmia, and thromboembolism. Ann Thorac Surg. Aug 2005;80(2):665-72. doi:10.1016/j.athoracsur.2005.02.024 12. Ono M, Boethig D, Goerler H, Lange M, Westhoff-Bleck M, Breymann T. Clinical outcome of patients 20 years after Fontan operation--effect of fenestration on late morbidity. Eur J Cardiothorac Surg. Dec 2006;30(6):923-9. doi:10.1016/j.ejcts.2006.08.025 13. Hosein RB, Clarke AJ, McGuirk SP, et al. Factors influencing early and late outcome following the Fontan procedure in the current era. The 'Two Commandments'? Eur J Cardiothorac Surg. Mar 2007;31(3):344-52; discussion 353. doi:10.1016/j.ejcts.2006.11.043 14. Nakano T, Kado H, Tatewaki H, et al. Results of extracardiac conduit total cavopulmonary connection in 500 patients. Eur J Cardiothorac Surg. Dec 2015;48(6):825-32; discussion 832. doi:10.1093/ejcts/ezv072 15. Pundi KN, Johnson JN, Dearani JA, et al. 40-Year Follow-Up After the Fontan Operation: Long-Term Outcomes of 1,052 Patients. J Am Coll Cardiol. Oct 13 2015;66(15):1700-10. doi:10.1016/j.jacc.2015.07.065 16. Nosal M, Valentik P, Kantorova A, Nagi AS, Sagat M, Poruban R. Factors influencing the intermediate outcome in patients with single-ventricle physiology after Fontan operation. Bratisl Lek Listy. 2010;111(7):373-7. 17. Dabal RJ, Kirklin JK, Kukreja M, et al. The modern Fontan operation shows no increase in mortality out to 20 years: a new paradigm. J Thorac Cardiovasc Surg. Dec 2014;148(6):2517-23 e1. doi:10.1016/j.jtcvs.2014.07.075 18. Poh CL, Xu M, Galati JC, et al. Surgical palliation in patients with a single ventricle and dextrocardia. J Thorac Cardiovasc Surg. Oct 2014;148(4):1475-80. doi:10.1016/j.jtcvs.2013.10.077 19. Pan JY, Lin CC, Chang JP. Fontan Operation in a Patient with Severe Hypoplastic Right Pulmonary Artery, Single Ventricle, and Heterotaxy Syndrome. Acta Cardiol Sin. Sep 2016;32(5):612-615. doi:10.6515/acs20160105a 20. Downing TE, Allen KY, Glatz AC, et al. Long-term survival after the Fontan operation: Twenty years of experience at a single center. J Thorac Cardiovasc Surg. Jul 2017;154(1):243-253 e2. doi:10.1016/j.jtcvs.2017.01.056 21. Budts W, Ravekes WJ, Danford DA, Kutty S. Diastolic Heart Failure in Patients With the Fontan Circulation: A Review. JAMA Cardiol. May 1 2020;5(5):590-597. doi:10.1001/jamacardio.2019.5459 22. Egbe AC, Connolly HM, Miranda WR, et al. Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease. Circ Heart Fail. Dec 2017;10(12)doi:10.1161/CIRCHEARTFAILURE.117.004515 23. Gewillig M, Goldberg DJ. Failure of the fontan circulation. Heart Fail Clin. Jan 2014;10(1):105-16. doi:10.1016/j.hfc.2013.09.010 24. Stern HJ. Fontan "Ten Commandments" revisited and revised. Pediatr Cardiol. Nov 2010;31(8):1131-4. doi:10.1007/s00246-010-9811-9 25. Becker K, Uebing A, Hansen JH. Pulmonary vascular disease in Fontan circulation-is there a rationale for pulmonary vasodilator therapies? Cardiovasc Diagn Ther. Aug 2021;11(4):1111-1121. doi:10.21037/cdt-20-431 26. Wang W, Hu X, Liao W, et al. The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials. Pulm Circ. Jan-Mar 2019;9(1):2045894018790450. doi:10.1177/2045894018790450 27. Dickinson MG, Bartelds B, Borgdorff MA, Berger RM. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol. Jul 1 2013;305(1):L1-14. doi:10.1152/ajplung.00031.2013 28. Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J. Mar 2014;35(11):691-700. doi:10.1093/eurheartj/eht437 29. Smadja DM, Gaussem P, Mauge L, et al. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation. Jan 27 2009;119(3):374-81. doi:10.1161/CIRCULATIONAHA.108.808246 30. Junhui Z, Xingxiang W, Guosheng F, Yunpeng S, Furong Z, Junzhu C. Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respir Med. Jul 2008;102(7):1073-9. doi:10.1016/j.rmed.2007.12.030 31. Yang JX, Pan YY, Zhao YY, Wang XX. Endothelial progenitor cell-based therapy for pulmonary arterial hypertension. Cell Transplant. 2013;22(8):1325-36. doi:10.3727/096368912X659899 32. Cantini-Salignac C, Lartaud I, Schrijen F, Atkinson J, Chabot F. Metalloproteinase-9 in circulating monocytes in pulmonary hypertension. Fundam Clin Pharmacol. Aug 2006;20(4):405-10. doi:10.1111/j.1472-8206.2006.00417.x 33. Frisdal E, Gest V, Vieillard-Baron A, et al. Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J. Nov 2001;18(5):838-45. doi:10.1183/09031936.01.00084601 34. Bienertova-Vasku J, Novak J, Vasku A. MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment. J Am Soc Hypertens. Mar 2015;9(3):221-34. doi:10.1016/j.jash.2014.12.011 35. Leopold JA, Maron BA. Molecular Mechanisms of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension. Int J Mol Sci. May 18 2016;17(5)doi:10.3390/ijms17050761 36. Thompson AAR, Lawrie A. Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. Trends Mol Med. Jan 2017;23(1):31-45. doi:10.1016/j.molmed.2016.11.005 37. Akgun AE, Yaylali YT, Secme M, Dodurga Y, Senol H. Kynurenine-PARP-1 Link Mediated by MicroRNA 210 May Be Dysregulated in Pulmonary Hypertension. Anatol J Cardiol. May 2022;26(5):388-393. doi:10.5152/AnatolJCardiol.2021.861 38. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail. Jun 2005;11(5 Suppl):S81-3. doi:10.1016/j.cardfail.2005.04.019 39. Kim YS, Karisa N, Jeon WY, Lee H, Kim YC, Ahn J. High-level production of N-terminal pro-brain natriuretic peptide, as a calibrant of heart failure diagnosis, in Escherichia coli. Appl Microbiol Biotechnol. Jun 2019;103(12):4779-4788. doi:10.1007/s00253-019-09826-8 40. Lewis RA, Durrington C, Condliffe R, Kiely DG. BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing? Eur Respir Rev. Jun 30 2020;29(156)doi:10.1183/16000617.0009-2020 41. Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R, Humbert M. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med. Jan 2007;101(1):69-75. doi:10.1016/j.rmed.2006.04.014 42. Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail. Jun 2005;11(5 Suppl):S76-80. doi:10.1016/j.cardfail.2005.04.009 43. Choi JH, Cho DK, Song YB, et al. Preoperative NT-proBNP and CRP predict perioperative major cardiovascular events in non-cardiac surgery. Heart. Jan 2010;96(1):56-62. doi:10.1136/hrt.2009.181388 44. Lechner E, Gitter R, Mair R, et al. Aminoterminal brain natriuretic peptide levels in children and adolescents after Fontan operation correlate with congestive heart failure. Pediatr Cardiol. Sep 2008;29(5):901-5. doi:10.1007/s00246-008-9225-0 45. Lowenthal A, Camacho BV, Lowenthal S, et al. Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease. Am J Cardiol. Mar 15 2012;109(6):866-72. doi:10.1016/j.amjcard.2011.10.049 46. Eindhoven JA, van den Bosch AE, Ruys TP, et al. N-terminal pro-B-type natriuretic peptide and its relationship with cardiac function in adults with congenital heart disease. J Am Coll Cardiol. Sep 24 2013;62(13):1203-12. doi:10.1016/j.jacc.2013.07.019 47. LaFarge CG, Miettinen OS. The estimation of oxygen consumption. Cardiovasc Res. Jan 1970;4(1):23-30. 48. Azakie A, McCrindle BW, Van Arsdell G, et al. Extracardiac conduit versus lateral tunnel cavopulmonary connections at a single institution: impact on outcomes. J Thorac Cardiovasc Surg. Dec 2001;122(6):1219-28. doi:10.1067/mtc.2001.116947 49. Kumar SP, Rubinstein CS, Simsic JM, Taylor AB, Saul JP, Bradley SM. Lateral tunnel versus extracardiac conduit Fontan procedure: a concurrent comparison. Ann Thorac Surg. Nov 2003;76(5):1389-96; discussion 1396-7. 50. Lee JR, Kwak J, Kim KC, et al. Comparison of lateral tunnel and extracardiac conduit Fontan procedure. Interact Cardiovasc Thorac Surg. Jun 2007;6(3):328-30. doi:10.1510/icvts.2006.146928 51. Fiore AC, Turrentine M, Rodefeld M, et al. Fontan operation: a comparison of lateral tunnel with extracardiac conduit. Ann Thorac Surg. Feb 2007;83(2):622-9; discussion 629-30. doi:10.1016/j.athoracsur.2006.09.070 52. Ono M, Kasnar-Samprec J, Hager A, et al. Clinical outcome following total cavopulmonary connection: a 20-year single-centre experience. Eur J Cardiothorac Surg. Oct 2016;50(4):632-641. doi:10.1093/ejcts/ezw091 53. Shiraishi S, Yagihara T, Kagisaki K, et al. Impact of age at Fontan completion on postoperative hemodynamics and long-term aerobic exercise capacity in patients with dominant left ventricle. Ann Thorac Surg. Feb 2009;87(2):555-60; discussion 560-1. doi:10.1016/j.athoracsur.2008.11.015 54. Allen KY, Downing TE, Glatz AC, et al. Effect of Fontan-Associated Morbidities on Survival With Intact Fontan Circulation. Am J Cardiol. Jun 1 2017;119(11):1866-1871. doi:10.1016/j.amjcard.2017.03.004 55. Iyengar AJ, Winlaw DS, Galati JC, et al. The extracardiac conduit Fontan procedure in Australia and New Zealand: hypoplastic left heart syndrome predicts worse early and late outcomes. Eur J Cardiothorac Surg. Sep 2014;46(3):465-73; discussion 473. doi:10.1093/ejcts/ezu015 56. Rogers LS, Glatz AC, Ravishankar C, et al. 18 years of the Fontan operation at a single institution: results from 771 consecutive patients. J Am Coll Cardiol. Sep 11 2012;60(11):1018-25. doi:10.1016/j.jacc.2012.05.010 57. Ohuchi H, Miyazaki A, Negishi J, et al. Hemodynamic determinants of mortality after Fontan operation. Am Heart J. Jul 2017;189:9-18. doi:10.1016/j.ahj.2017.03.020 58. Azakie A, Merklinger SL, Williams WG, Van Arsdell GS, Coles JG, Adatia I. Improving outcomes of the Fontan operation in children with atrial isomerism and heterotaxy syndromes. Ann Thorac Surg. Nov 2001;72(5):1636-40. doi:10.1016/s0003-4975(01)03039-9 59. Bartz PJ, Driscoll DJ, Dearani JA, et al. Early and late results of the modified fontan operation for heterotaxy syndrome 30 years of experience in 142 patients. J Am Coll Cardiol. Dec 5 2006;48(11):2301-5. doi:10.1016/j.jacc.2006.07.053 60. Kim SJ, Kim WH, Lim HG, Lee CH, Lee JY. Improving results of the Fontan procedure in patients with heterotaxy syndrome. Ann Thorac Surg. Oct 2006;82(4):1245-51. doi:10.1016/j.athoracsur.2006.04.082 61. Naito Y, Aoki M, Matsuo K, Nakajima H, Aotsuka H, Fujiwara T. Intracardiac Fontan procedure for heterotaxy syndrome with complex systemic and pulmonary venous anomalies. Eur J Cardiothorac Surg. Jan 2010;37(1):197-203. doi:10.1016/j.ejcts.2009.06.055 62. Stamm C, Friehs I, Duebener LF, et al. Improving results of the modified Fontan operation in patients with heterotaxy syndrome. Ann Thorac Surg. Dec 2002;74(6):1967-77; discussion 1978. doi:10.1016/s0003-4975(02)04124-3 63. Marathe SP, Cao JY, Celermajer D, et al. Outcomes of the Fontan Operation for Patients With Heterotaxy: A Meta-Analysis of 848 Patients. Ann Thorac Surg. Jan 8 2020;doi:10.1016/j.athoracsur.2019.11.027 64. Gentles TL, Mayer JE, Jr., Gauvreau K, et al. Fontan operation in five hundred consecutive patients: factors influencing early and late outcome. J Thorac Cardiovasc Surg. Sep 1997;114(3):376-91. doi:10.1016/s0022-5223(97)70183-1 65. Stewart RD, Pasquali SK, Jacobs JP, et al. Contemporary Fontan operation: association between early outcome and type of cavopulmonary connection. Ann Thorac Surg. Apr 2012;93(4):1254-60; discussion 1261. doi:10.1016/j.athoracsur.2012.01.060 66. Kim SJ, Kim WH, Lim HG, Lee JY. Outcome of 200 patients after an extracardiac Fontan procedure. J Thorac Cardiovasc Surg. Jul 2008;136(1):108-16. doi:10.1016/j.jtcvs.2007.12.032 67. Chiu SN, Shao PL, Wang JK, et al. Low immunoglobulin M memory B-cell percentage in patients with heterotaxy syndrome correlates with the risk of severe bacterial infection. Pediatr Res. Feb 2016;79(2):271-7. doi:10.1038/pr.2015.221 68. Carins TA, Shi WY, Iyengar AJ, et al. Long-term outcomes after first-onset arrhythmia in Fontan physiology. J Thorac Cardiovasc Surg. Nov 2016;152(5):1355-1363 e1. doi:10.1016/j.jtcvs.2016.07.073 69. Rijnberg FM, Blom NA, Sojak V, et al. A 45-year experience with the Fontan procedure: tachyarrhythmia, an important sign for adverse outcome. Interact Cardiovasc Thorac Surg. Sep 1 2019;29(3):461-468. doi:10.1093/icvts/ivz111 70. Rekawek J, Kansy A, Miszczak-Knecht M, et al. Risk factors for cardiac arrhythmias in children with congenital heart disease after surgical intervention in the early postoperative period. J Thorac Cardiovasc Surg. Apr 2007;133(4):900-4. doi:10.1016/j.jtcvs.2006.12.011 71. Valsangiacomo E, Schmid ER, Schupbach RW, et al. Early postoperative arrhythmias after cardiac operation in children. Ann Thorac Surg. Sep 2002;74(3):792-6. doi:10.1016/s0003-4975(02)03786-4 72. Hsu DT. The Fontan operation: the long-term outlook. Curr Opin Pediatr. Oct 2015;27(5):569-75. doi:10.1097/MOP.0000000000000271 73. Malhotra SP, Ivy DD, Mitchell MB, et al. Performance of cavopulmonary palliation at elevated altitude: midterm outcomes and risk factors for failure. Circulation. Sep 30 2008;118(14 Suppl):S177-81. doi:10.1161/CIRCULATIONAHA.107.751784 74. Yoshimura N, Yamaguchi M, Oshima Y, et al. Risk factors influencing early and late mortality after total cavopulmonary connection. Eur J Cardiothorac Surg. Sep 2001;20(3):598-602. doi:10.1016/s1010-7940(01)00857-0 75. Stephens EH, Dearani JA, Niaz T, Arghami A, Phillips SD, Cetta F. Effect of Earlier Atrioventricular Valve Intervention on Survival After the Fontan Operation. Am J Cardiol. Dec 15 2020;137:103-110. doi:10.1016/j.amjcard.2020.09.028 76. Lin HC, Wu MH, Wang JK, et al. Perioperative outcomes of Fontan operation: Impact of heterotaxy syndrome. J Formos Med Assoc. Feb 3 2021;doi:10.1016/j.jfma.2021.01.014 77. Chiu SN, Shao PL, Wang JK, et al. Severe bacterial infection in patients with heterotaxy syndrome. J Pediatr. Jan 2014;164(1):99-104 e1. doi:10.1016/j.jpeds.2013.08.051 78. Julsrud PR, Weigel TJ, Van Son JA, et al. Influence of ventricular morphology on outcome after the Fontan procedure. Am J Cardiol. Aug 1 2000;86(3):319-23. doi:10.1016/s0002-9149(00)00922-x 79. Tweddell JS, Nersesian M, Mussatto KA, et al. Fontan palliation in the modern era: factors impacting mortality and morbidity. Ann Thorac Surg. Oct 2009;88(4):1291-9. doi:10.1016/j.athoracsur.2009.05.076 80. Lechner E, Schreier-Lechner EM, Hofer A, et al. Aminoterminal brain-type natriuretic peptide levels correlate with heart failure in patients with bidirectional Glenn anastomosis and with morbidity after the Fontan operation. J Thorac Cardiovasc Surg. Sep 2009;138(3):560-4. doi:10.1016/j.jtcvs.2009.03.005 81. Qu J, Liang H, Zhou N, et al. Perioperative NT-proBNP level: Potential prognostic markers in children undergoing congenital heart disease surgery. J Thorac Cardiovasc Surg. Aug 2017;154(2):631-640. doi:10.1016/j.jtcvs.2016.12.056 82. Chiu SN, Weng KP, Lin MC, et al. Congenital heart disease with pulmonary artery hypertension in an Asian cohort-initial report from TACHYON (TAiwan congenital heart disease associated with pulmonarY arterial hypertension) registry. Int J Cardiol. Oct 15 2020;317:49-55. doi:10.1016/j.ijcard.2020.05.086 83. Salazar JD, Zafar F, Siddiqui K, et al. Fenestration during Fontan palliation: now the exception instead of the rule. J Thorac Cardiovasc Surg. Jul 2010;140(1):129-36. doi:10.1016/j.jtcvs.2010.03.013 84. Fan F, Liu Z, Li S, et al. Effect of Fenestration on Early Postoperative Outcome in Extracardiac Fontan Patients with Different Risk Levels. Pediatr Cardiol. Apr 2017;38(4):643-649. doi:10.1007/s00246-016-1561-x 85. Mitchell ME, Ittenbach RF, Gaynor JW, Wernovsky G, Nicolson S, Spray TL. Intermediate outcomes after the Fontan procedure in the current era. J Thorac Cardiovasc Surg. Jan 2006;131(1):172-80. doi:10.1016/j.jtcvs.2005.08.047 86. Alphonso N, Baghai M, Sundar P, Tulloh R, Austin C, Anderson D. Intermediate-term outcome following the fontan operation: a survival, functional and risk-factor analysis. Eur J Cardiothorac Surg. Oct 2005;28(4):529-35. doi:10.1016/j.ejcts.2005.06.035 87. Iyengar AJ, Winlaw DS, Galati JC, et al. Trends in Fontan surgery and risk factors for early adverse outcomes after Fontan surgery: the Australia and New Zealand Fontan Registry experience. J Thorac Cardiovasc Surg. Aug 2014;148(2):566-75. doi:10.1016/j.jtcvs.2013.09.074 | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/79225 | - |
dc.description.abstract | 背景: 單一心室複雜性先天性心臟病是先天性心臟病中罕見的一個類別,無法利用手術建立雙心室循環。異位症是其中的一個特別族群,其定義為胸腹器官左右位置異常。因為異位症的解剖構造更為複雜,手術修補困難程度更高。Fontan類手術是單一心室複雜性先天性心臟病達到長期存活的標準手術,手術中,唯一有功能的心室留給體循環使用。因為沒有有功能/肺動脈下的右心室,體靜脈完全被動地回流至肺部。因此有必要在整個通道保持低的肺動脈壓力和肺血管阻力。如果Fontan循環的血液動力學狀況不良,即稱為Fontan衰竭。造成Fontan衰竭最重要的原因是Fontan壓力升高及肺血管阻力指數升高。即使是些微的肺血管阻力指數升高,心輸出量就會明顯降低。循環目前手術前後和長期的死亡率仍然不低,因此有需要建立一個包含肺動脈壓和肺動脈阻力指數在內,更完整的手術前篩選原則。現今對Fontan衰竭最主要的治療藥物是肺血管舒張劑,可以降低Fontan/肺動脈壓力及肺血管阻力指數。但是,此種治療對死亡率沒有明顯統計差異。此外,分析生物指標可能有額外幫助。在肺動脈高壓的病理機轉中,血管內皮指標(循環內皮細胞、血管內皮前驅細胞)、胞外基質指標(基質金屬蛋白酶1和2)和微小RNA都有參與原發性肺動脈高壓及Eisenmenger症候群的病理機轉。但是否可以在Fontan手術中應用這些肺血管重塑的生物因子,目前仍然未知。 目標: (1)我們回溯性分析台大兒童醫院的Fontan病人群體,以得知手術前後和術後長期的危險因子和存活率。 (2)我們利用術前的生物指標納入預測模型,以判別進行手術的危險程度。 方法:對於手術前後和長期預後,我們回溯分析所有過去30年來單一心室複雜性先天性心臟病的病患病歷資料。此外,我們前瞻性對於所有準備進行Fontan手術而入院進行心導管術前評估的病患分析肺動脈高壓相關的生物指標。主要試驗終點指標為死亡、Fontan循環拆除手術和心臟移植。次要試驗終點指標為需要住院治療心衰竭。 結果: (1)對於Fontan手術前後的預後方面:總共納入154位病患,男女各為92及62人,平均進行Fontan手術的年齡是5.1 ± 2.2歲。有11位(7.1%)病患發生手術前後死亡。2008年後的無事件存活率比較早期更好(分別為95.7%及78.4%,P = 0.003)。在我們的病人群體中,右心室同位症(47位)佔全部異位症(51位)的大多數(92.1%)。手術前後無事件存活率為91.6%。於單一變項分析中,異位症病患的手術前後死亡率為15.7%,高於其他非異位症的複雜性先天性心臟病病患的4.9%(P = 0.032)。兩組病患加護病房住院時間過久及持續胸水引流時間過長的比率沒有統計顯著意義。多變項回歸分析發現和不良預後相關的術前危險因子有手術時間在2007年之前和較高的肺動脈壓。在經過術前肺動脈壓和手術年份調整之後,異位症不再是重要的預後不良因子。使用接受者操作特徵曲線決定術前肺動脈壓力及術後中心靜脈壓的最佳切點分別為14 mmHg(敏感度0.600,特異度0.787)及16 mmHg(敏感度0.800,特異度0.769)。 (2)對於長期預後,我們納入110位病患(62位男性及48位女性),平均接受Fontan手術的年齡為4.1(3.4,5.8)歲。其中91位病患有術前血清log10 N端前腦利鈉肽的數據。使用單一變項Cox迴歸分析發現,對於死亡、Fontan循環拆解手術和心臟移植,心室收縮功能不良、肺動脈壓力大於或等於15 mmHg、肺血管阻力指數以及log10 N端前腦利鈉肽數值和不良預後有關。然而在多變項Cox迴歸分析發現log10 N端前腦利鈉肽數值(風險比:24.08,95%信賴區間:3.83-151.24,P = 0.001)是唯一顯著可以預測所有主要次要終點指標的因子。接受者操作特徵曲線,N端前腦利鈉肽可用以預測主要預後指標的最佳切點是280 pg/mL (log10 N端前腦利鈉肽2.45),其敏感度為0.75而特異度為0.71。根據使用肺動脈壓、肺血管阻力指數及N端前腦利鈉肽可以建立一個評分系統,其危險分級與Fontan手術的預後相關。在術前N端前腦利鈉肽高於或等於280 pg/mL與低於280 pg/mL的病人次族群相比,有較高的術前肺血管阻力指數(1.59 [0.47,2.47] 相比於0.66 [0.31,1.37],P = 0.007)、較低的術後脈衝式血液氧氣濃度(88.3 ± 8.8相比於91.5 ± 5.8,P = 0.037)以及較高的術後Fontan壓力(15.5 ± 4.1 vs. 13.5 ± 3.3, P = 0.012)。使用Cox迴歸分析術前N端前腦利鈉肽高於或等於280 pg/mL也和較差的無事件存活率(風險比:6.30 [1.27-31.27],P = 0.024)相關。對於需住院的心衰竭,多變項迴歸分析中,唯獨有log10 N端前腦利鈉肽和不良預後相關。 結論: (1)目前Fontan手術前後的的預後近年來已經大幅進步。異位症病人手術前後的預後較差,可能和本身較差的血液動力學因子相關,經過血液動力學因子的調整過後,異位症本身並非可以預測手術前後死亡的因子。術前的肺動脈壓力和術後的中心靜脈壓是預測Fontan術後預後的最重要指標,異位症則不相關。 (2)較高的N端前腦利鈉肽與不良預後有關。使用術前的肺動脈壓力、肺血管阻力指標及N端前腦利鈉肽建立分數模型可以對於中期預後進行危險分級,選擇真正適合進行Fontan手術的病人。 未來計畫: 我們計畫分析其他肺動脈高壓的生物指標於Fontan手術的效用,以作為可替代診斷性心導管的非侵入性指標。病患於術前入院接受心導管檢查時納入收案,收集血液檢體計算其中的CEC和EPC數量。主要試驗終點為死亡、Fontan循環拆除手術及心臟移植。次要試驗終點為因為心衰竭而住院。此外也分析CEC和EPC數量和血液動力學數值的關聯性。 | zh_TW |
dc.description.abstract | Background: Single-ventricular complex congenital heart disease (SV-CHD) is a rare type of congenital heart disease (CHD), which is unable to achieve biventricular repair. Heterotaxy syndrome is a special disease group in SV-CHD. It is defined as having abnormality of the thoraco-abdominal organs in the left-right axis. The more complex anatomical structure results in the more difficulty for repair or palliation. Fontan-type operation is the standard surgical procedure for achieving long-term survival in SV-CHD. The only one functional ventricle is reserved as the systemic ventricle. Without the pumping of the functional/subpulmonary right ventricle, the driving force of systemic venous return to the lungs is totally passive. Therefore, low pulmonary artery pressure and pulmonary vascular resistance are required. Fontan failure developed if the hemodynamic condition of Fontan circulation goes wrong. The most important causes that lead to Fontan failure are elevated Fontan pressure and pulmonary vascular resistance index (PVRI). Even a slight increase in PVRI may lead to markedly decreased cardiac output. Since the perioperative and late mortality/morbidity is still not low, a more comprehensive patient selection criterion for preoperative risk factors, including pulmonary artery pressure (PAP) and PVRI measurement, and analyses of biomarkers may be beneficial. The mainstay of treatment for Fontan failure is using pulmonary vasodilators to decrease the Fontan /pulmonary artery pressure and PVRI; however, there is no significant change in mortality. For the pathogenesis of pulmonary hypertension (PAH), endothelial markers (circulating endothelial cell [CEC] and endothelial progenitor cell [EPC]), extracellular matrix markers (matrix metalloproteinase [MMP]-1 and 2), and microRNA (miRNA) are involved in the pathogenesis of idiopathic PAH and Eisenmenger syndrome. However, the role of pulmonary vascular remodeling and the application of these biomarkers on Fontan operation are still unknown. Objectives: (1) We analyze the cohort of Fontan patients in National Taiwan University Children’s Hospital retrospectively to understand the risk factors and survival of perioperative and long-term outcomes. (2) We construct a risk-scoring model including only preoperative risk factors for risk stratification. Methods: Retrospectively, medical records of all patients with SV-CHD in the past 30 years were analyzed for perioperative and long term outcome. The primary outcomes were death, Fontan takedown, and cardiac transplantation. The secondary outcomes were heart failure requiring hospitalization. Results: (1) Perioperative outcomes of Fontan operation: A total of 154 patients, with a male to female ratio of 92:62, were enrolled, and the mean age at Fontan operation was 5.1 ± 2.2 years. Perioperative mortality occurred in 11 (7.1%) patients. Event-free survival after 2008 was better than that before 2007 (95.7% vs. 78.4%, respectively, P = 0.003). In our cohort, RAI (47 of 51 patients, 92.1%) comprised the majority of HS. Overall perioperative event-free survival was 91.6%. In univariable analysis, perioperative mortality was 15.7% in the patients with HS compared with 4.9% in the patients with other complex CHDs (P = 0.032). In multivariable regression analysis, preoperative risk factors including operation year before 2007 and high PAP were associated with worse outcomes. Heterotaxy syndrome was not a predictor of worse outcome after adjusting for preoperative PAP and operation era. We used the receiver operating characteristic curve to determine the cut-off points of 14 mmHg for preoperative PAP (sensitivity: 0.600, specificity: 0.787) and of 16 mmHg for postoperative CVP (sensitivity: 0.800, specificity: 0.769), with the best sensitivity and specificity. (2) For mid- to long-term outcomes, we enrolled 110 patients (62 men and 48 women). Their mean age at the time of the Fontan operation was 4.1 (3.4, 5.8) years. Preoperative NT-proBNP data were available for 91 patients. For death, Fontan takedown, and heart transplantation, in univariable Cox regression analysis, abnormal ventricular contractility, PAP ≥15 mmHg, PVRI, and log10NT-proBNP were associated with poor outcomes; whereas in multivariable analysis, only log10NT-proBNP (HR: 24.08, 95% CI: 3.83-151.24, P = 0.001) was associated with poor outcomes. According to receiver operating characteristic (ROC) curve, the best cut point of NT-proBNP value for predicting primary outcomes was 280 pg/mL (log10NT-proBNP 2.45), with the sensitivity 0.75 and specificity 0.71. A scoring system including factors of PAP, PVRI, and NT-proBNP was established, and the risk stratification is associated with outcomes after the Fontan operation. High preoperative PVRI (1.59 [0.47, 2.47] vs. 0.66 [0.31, 1.37], P = 0.007), low postoperative SpO2 (88.3 ± 8.8 vs. 91.5 ± 5.8, P = 0.037), and high postoperative Fontan pressure (15.5 ± 4.1 vs. 13.5 ± 3.3, P = 0.012) were observed in the subgroup NT-proBNP ≥ 280 pg/mL. NT-proBNP ≥ 280 pg/mL was also associated with poor event-free survival (HR 6.30 [1.27-31.27], P = 0.024) in Cox regression analysis. For heart failure requiring hospitalization and postoperative tachyarrhythmias, only log10NT-proBNP was associated with poor outcomes in multivariable analysis. Conclusion: (1) Surgical outcomes of Fontan operation in the current era are excellent. Patients of heterotaxy syndrome have higher perioperative mortality, which may relate to poor hemodynamic factors. Preoperative PAP and postoperative CVP are the most essential predictors of the outcomes of Fontan operation, whereas heterotaxy syndrome is not. (2) High preoperative NT-proBNP was associated with poor outcomes after the Fontan operation. A scoring system using preoperative PAP, PVRI, and NT-proBNP levels may stratify mid-term risks and can be used to select good candidates for the Fontan operation. Future Plans: We plan to analyze biomarkers of PAH in patients undergoing Fontan operation in order to search for a non-invasive tool for preoperative evaluation. Patients are prospectively enrolled at the time of admission for preoperative cardiac catheterization. Blood samples are collected for circulating endothelial cells (CEC) and epithelial progenitor cells (EPC) counts. The primary endpoints are death, Fontan takedown, and heart transplantation. The secondary endpoint is heart failure requiring hospitalization. Associations of CEC and EPC counts and hemodynamic values are also checked. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2022-11-16T17:02:27Z
No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2022-11-16T17:02:27Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員會審定書 …………………………………………………………… i 謝辭 …………………………………………………………… ii 中文摘要 …………………………………………………………… iii 英文摘要 …………………………………………………………… vi 縮寫對照表 …………………………………………………………… ix 第一章 Complex Congenital Heart Diseases and Fontan Operation ……………………………………………… 1 1.1 Complex Congenital Heart Disease …………………… 1 1.2 Heterotaxy Syndrome ………………………………… 1 1.3 Fontan Operation and Fontan Circulation ……………… 2 1.4 Mortality of Fontan Operation ………………………… 3 1.5 Fontan Failure ………………………………………… 6 1.6 Selection Criteria of Fontan Operation ………………… 7 1.7 Treatment of Fontan Failure …………………………… 7 1.8 Pathophysiology of Pulmonary Arterial Hypertension … 8 1.9 Biomarkers in Pulmonary Arterial Hypertension ……… 9 1.10 N-Terminal Pro-Brain Natriuretic Peptide …………… 10 第二章 Aims …………………………………………………… 12 2.1 Fontan Outcomes in Taiwan …………………………… 12 2.2 Heterotaxy Syndrome ………………………………… 12 2.3 Risk Scoring System …………………………………… 12 2.4 Biomarkers of PAH …………………………………… 12 第三章 Patients and Methods ………………………………… 13 3.1 Institutional Review Board Approval ………………… 13 3.2 Study Site …………………………………………… 13 3.3 Patient Enrollment and Sample Collection …………… 13 3.4 Definitions …………………………………………… 13 3.5 Outcomes ……………………………………………… 14 3.6 Statistical analysis …………………………………… 14 第四章 Results ………………………………………………… 16 4.1 Perioperative Outcomes of Fontan Operation ………… 16 4.2 Mid- to Long-Term Outcomes of Fontan Operation / NT-proBNP …………………………………………… 18 第五章 Discussion ……………………………………………… 22 5.1 Perioperative Outcomes of Fontan Operation ………… 22 5.2 Mid- to Long-Term Outcomes of Fontan Operation / NT-proBNP ………… 26 第六章 Future Plans …………………………………………… 31 6.1 Aim …………………………………………………… 31 6.2 Methods ………………………………………………… 31 6.3 Preliminary Results …………………………………… 32 第七章 Source of Funding ……………………………………… 35 參考文獻 …………………………………………………………… 36 表 …………………………………………………………… 45 圖 …………………………………………………………… 82 | - |
dc.language.iso | en | - |
dc.title | Fontan單一心室手術之預後分析:危險因子、生物指標及開窗手術的關聯性 | zh_TW |
dc.title | Outcomes After Fontan-Type Operation: Risk Factors, Impact of Biomarkers and Association with Fenestration | en |
dc.title.alternative | Outcomes After Fontan-Type Operation: Risk Factors, Impact of Biomarkers and Association with Fenestration | - |
dc.type | Thesis | - |
dc.date.schoolyear | 111-1 | - |
dc.description.degree | 博士 | - |
dc.contributor.oralexamcommittee | 陳祈玲;吳俊明;鄭敬楓 | zh_TW |
dc.contributor.oralexamcommittee | Chi-Ling Chen;Jing-Ming Wu;Ching-Feng Cheng | en |
dc.subject.keyword | Fontan手術,先天性心臟病,異位症,肺高壓,N端前腦利鈉肽, | zh_TW |
dc.subject.keyword | Fontan operation,Congenital heart disease,Heterotaxy syndrome,Pulmonary hypertension,N-terminal pro-brain natriuretic peptide, | en |
dc.relation.page | 92 | - |
dc.identifier.doi | 10.6342/NTU202204248 | - |
dc.rights.note | 同意授權(限校園內公開) | - |
dc.date.accepted | 2022-10-03 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 臨床醫學研究所 | - |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-0210202222011500.pdf 授權僅限NTU校內IP使用(校園外請利用VPN校外連線服務) | 3.52 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。